Idiopathic Pulmonary Fibrosis Treatment Market Revenue to Hit USD 7.81 Billion by 2034, Driven by 6.9% Growth Rate | PMR
20. November 2024 06:40 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Market Overview: Polaris Market Research's latest analysis reveals that the market for idiopathic pulmonary fibrosis treatment is on a growth...
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
14. November 2024 16:20 ET
|
GRI Bio, Inc.
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study Topline...
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
04. November 2024 08:30 ET
|
Surrozen, Inc.
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary FIbrosis
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
24. Oktober 2024 08:30 ET
|
GRI Bio, Inc.
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of...
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
16. Oktober 2024 08:45 ET
|
GRI Bio, Inc.
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis ...
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
16. September 2024 06:05 ET
|
Boehringer Ingelheim
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52...
RS BioTherapeutics Announces Research Collaboration with University of Colorado School of Medicine
08. Juli 2024 10:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., July 08, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases...
Pulmonary Fibrosis Treatment Market Research: Escalating Demand for Innovative Treatment Options Amidst Escalating Prevalence - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031
24. Mai 2024 03:29 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Pulmonary Fibrosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
20. Mai 2024 08:45 ET
|
GRI Bio, Inc.
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score...
RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
30. April 2024 10:00 ET
|
RS BioTherapeutics
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.